In this regard, our observations may be supported by the documented therapeutic potential of AT1 receptor blockers not only in the management of progressive diabetic nephropathy [28] but also in alleviating diabetes-associated hepatic fibrosis [55]. Here, AGTR1 is linked to diabetic kidney disease.